We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Alpine Immune Sciences Inc | NASDAQ:ALPN | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.01 | 0.02% | 64.61 | 64.47 | 64.72 | 64.65 | 64.58 | 64.65 | 1,924,182 | 01:00:00 |
Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today announced that members of its management team will present at the following investor conferences in January 2022:
H.C. Wainwright BIOCONNECT Virtual Conference Date: Monday, January 10, 2022 Time: Available on demand beginning 7:00 a.m. ET/4:00 a.m. PT Event: Company Presentation
J.P. Morgan Healthcare Conference Date: Thursday, January 13, 2022 Time: 12:00 p.m. ET/9:00 a.m. PT Event: Company Presentation
Webcasts of the H.C. Wainwright, and J.P. Morgan presentations will be available online in the investor relations section of the company’s website at https://ir.alpineimmunesciences.com/events. A replay of the presentations will be available on the company website for 90 days following the webcast.
About Alpine Immune Sciences, Inc.
Alpine Immune Sciences, Inc. is committed to leading a new wave of immune therapeutics. With world-class research and development capabilities, a highly productive scientific platform, and a proven management team, Alpine is seeking to create first- or best-in-class multifunctional immunotherapies via unique protein engineering technologies to improve patients’ lives. Alpine has entered into strategic collaborations with leading global biopharmaceutical companies and has a diverse pipeline of clinical and preclinical candidates in development. For more information, visit www.alpineimmunesciences.com. Follow @AlpineImmuneSci on Twitter and LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220104005826/en/
Investor Relations Alex Sharif Director, Investor Relations and Corporate Development Alpine Immune Sciences, Inc 206-788-4545 ir@alpineimmunesciences.com
Media Relations Kelli Perkins Red House Kelli@redhousecomms.com
1 Year Alpine Immune Sciences Chart |
1 Month Alpine Immune Sciences Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions